Achilles Therapeutics (ACHL) Short Interest Ratio & Short Volume

Short interest is the volume of Achilles Therapeutics shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 74,800 shares of ACHL short. 0.19% of Achilles Therapeutics' shares are currently sold short. Learn More on Achilles Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.19% of Achilles Therapeutics' floating shares are currently sold short.

Achilles Therapeutics saw a increase in short interest in the month of March. As of March 31st, there was short interest totaling 74,800 shares, an increase of 8.6% from the previous total of 68,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Achilles Therapeutics currently has issued a total of 39,880,000 shares. Some of Achilles Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Achilles Therapeutics currently has a public float of 38,670,000 shares.

0.19% of Achilles Therapeutics' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Achilles Therapeutics: MiNK Therapeutics, Inc. (0.42%), Protara Therapeutics, Inc. (0.71%), IN8bio, Inc. (0.18%), Pluri Inc. (0.33%), Cyclo Therapeutics, Inc. (0.36%), Estrella Immunopharma, Inc. (0.08%), OKYO Pharma Limited (0.99%), Evaxion Biotech A/S (0.82%), Quince Therapeutics, Inc. (6.21%), Aptose Biosciences Inc. (0.92%),

As of the most recent reporting period, the following stocks had the largest short interest positions: TC Energy Co. ($4.49 billion), T-Mobile US, Inc. ($3.94 billion), General Motors ($3.34 billion), Charter Communications, Inc. ($3.32 billion), Occidental Petroleum Co. ($3.21 billion), Super Micro Computer, Inc. ($3.13 billion), Coinbase Global, Inc. ($3.08 billion), Moderna, Inc. ($2.28 billion), Tractor Supply ($2.24 billion), and Royal Caribbean Cruises Ltd. ($2.14 billion). View all of the most shorted stocks.

Short selling ACHL is an investing strategy that aims to generate trading profit from Achilles Therapeutics as its price is falling. ACHL shares are trading down $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Achilles Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of ACHL, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ACHL, twice per month. The most recent reporting period available is March, 31 2024.